{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T17:21:51Z","timestamp":1791566511159,"version":"4.3.4"},"reference-count":34,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T00:00:00Z","timestamp":1737417600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cell. Infect. Microbiol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>\n                      Little was known about the characteristics of low respiratory tract (LRT) microbiota of refractory\n                      <jats:italic>M. pneumoniae<\/jats:italic>\n                      pneumonia (RMPP) in children before and after the COVID-19 pandemic.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Forty-two children diagnosed with RMPP in 2019 (Y2019 group) and 33 children diagnosed with RMPP in 2023 (Y2023 group), entered into the study. The characteristics of the clinical findings were examined, and the LRT microbiota was analyzed by metagenomic next generation sequencing.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The ratio of consolidate, atelectasis, lung necrosis, and erythema multiforme in Y2023 group was significantly higher than that in Y2019 (\n                      <jats:italic>P<\/jats:italic>\n                      &amp;lt;0.05).\n                      <jats:italic>Mycoplasmoides pneumoniae<\/jats:italic>\n                      was the top species of the LRT microbiota in both groups. The rate of macrolide resistance MP in Y2023 was significantly higher than that in Y2019 (\n                      <jats:italic>P<\/jats:italic>\n                      &amp;lt;0.05), and the mutant site was all 23S rRNA A2063G. There were no significant differences in \u03b1-diversity and \u03b2-diversity of LRT microbiota between Y2019 and Y2023 group.\n                      <jats:italic>Trichoderma citrinoviride, Canine mastadenovirus A, Ralstonia pickettii, Lactococcus lactis, Pseudomonas aeruginosa<\/jats:italic>\n                      were the biomarkers of LRT microbiota in children with RMPP of Y2023. The abundance of\n                      <jats:italic>Mycoplasmoides pneumoniae<\/jats:italic>\n                      positively correlated with the levels of D-dimer and LDH, negatively correlated with the counts of CD3\n                      <jats:sup>+<\/jats:sup>\n                      T cells, CD8\n                      <jats:sup>+<\/jats:sup>\n                      T cells, CD19\n                      <jats:sup>+<\/jats:sup>\n                      B cells and CD16\n                      <jats:sup>+<\/jats:sup>\n                      CD56\n                      <jats:sup>+<\/jats:sup>\n                      NK cells.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>\n                      Our study showed that high abundance of MP was correlated with the severity of RMPP and decrease of immune cells.\n                      <jats:italic>Trichoderma citrinoviride, Canine mastadenovirus A, Ralstonia pickettii, Lactococcus lactis, Pseudomonas aeruginosa<\/jats:italic>\n                      were the biomarkers in microbiota of LRT in children with RMPP post COVID-19 era.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fcimb.2024.1438777","type":"journal-article","created":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T09:02:08Z","timestamp":1737450128000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":9,"title":["Characteristics of lower respiratory microbiota in children\u2019s refractory Mycoplasma pneumoniae pneumonia pre- and post-COVID-19 era"],"prefix":"10.3389","volume":"14","author":[{"given":"Zhimin","family":"Xi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinglong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Libo","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aizhen","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,1,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"604","DOI":"10.21037\/tp-20-404","article-title":"Highly homogeneous microbial communities dominated by Mycoplasma pneumoniae instead of increased resistance to macrolide antibiotics is the characteristic of lower respiratory tract microbiome of children with refractory Mycoplasma pneumoniae pneumonia","volume":"10","author":"Chen","year":"2021","journal-title":"Transl. Pediatr."},{"key":"B2","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1016\/j.tim.2019.08.001","article-title":"The gut microbiota in the first decade of life","volume":"27","author":"Derrien","year":"2019","journal-title":"Trends Microbiol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1080\/14787210.2019.1621168","article-title":"Relationship between nasopharyngeal microbiota and patient\u2019s susceptibility to viral infection","volume":"17","author":"Dubourg","year":"2019","journal-title":"Expert Rev. Anti Infect. Ther."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10096-017-3076-7","article-title":"Impact of nasopharyngeal microbiota on the development of respiratory tract diseases","volume":"37","author":"Esposito","year":"2018","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"B5","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s12879-020-05700-5","article-title":"Clinical significance of D-dimer levels in refractory Mycoplasma pneumoniae pneumonia","volume":"21","author":"Huang","year":"2021","journal-title":"BMC Infect. Dis."},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2023.1181402","article-title":"The clinical significance of macrolide resistance in pediatric Mycoplasma pneumoniae infection during COVID-19 pandemic","volume":"13","author":"Jiang","year":"2023","journal-title":"Front. Cell Infect. Microbiol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"2425","DOI":"10.1099\/jgv.0.000920","article-title":"Early nasopharyngeal microbial signature associated with severe influenza in children: a retrospective pilot study","volume":"98","author":"Langevin","year":"2017","journal-title":"J. Gen. Virol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"101338","DOI":"10.1016\/j.accpm.2023.101338","article-title":"Mycoplasma pneumoniae is back! Is it the next pandemic","volume":"43","author":"Larcher","year":"2024","journal-title":"Anaesth Crit. Care Pain Med."},{"key":"B9","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.jfma.2020.08.018","article-title":"Severe Mycoplasma pneumoniae pneumonia requiring intensive care in children, 2010-2019","volume":"120","author":"Lee","year":"2021","journal-title":"J. Formos Med. Assoc."},{"key":"B10","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/j.jmii.2020.03.030","article-title":"Altered chemokine profile in Refractory Mycoplasma pneumoniae pneumonia infected children","volume":"54","author":"Lee","year":"2021","journal-title":"J. Microbiol. Immunol. Infect."},{"key":"B11","doi-asserted-by":"publisher","first-page":"20075","DOI":"10.2807\/ese.17.05.20075-en","article-title":"European working group on Mycoplasma pneumoniae surveillance. surveillance status and recent data for Mycoplasma pneumoniae infections in the European Union and European Economic Area, January 2012","volume":"17","author":"Lenglet","year":"2012","journal-title":"Euro Surveill."},{"key":"B12","doi-asserted-by":"publisher","first-page":"136","DOI":"10.2174\/1872213X12666180621163821","article-title":"Community-acquired pneumonia in children","volume":"12","author":"Leung","year":"2018","journal-title":"Recent Pat. Inflammation Allergy Drug Discovery"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1016\/S0140-6736(20)30920-X","article-title":"SARS-CoV-2 and viral sepsis: observations and hypotheses","volume":"395","author":"Li","year":"2020","journal-title":"Lancet."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.4187\/respcare.03920","article-title":"Lactate dehydrogenase as a biomarker for prediction of refractory mycoplasma pneumoniae pneumonia in children","volume":"60","author":"Lu","year":"2015","journal-title":"Respir. Care"},{"key":"B15","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1038\/nrmicro.2017.14","article-title":"The microbiota of the respiratory tract: gatekeeper to respiratory health","volume":"15","author":"Man","year":"2017","journal-title":"Nat. Rev. Microbiol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/S2213-2600(18)30449-1","article-title":"Bacterial and viral respiratory tract microbiota and host characteristics in children with lower respiratory tract infections: a matched case-control study","volume":"7","author":"Man","year":"2019","journal-title":"Lancet Respir. Med."},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/S2666-5247(23)00182-9","article-title":"Mycoplasma pneumoniae: gone forever","volume":"4","author":"Meyer Sauteur","year":"2023","journal-title":"Lancet Microbe"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/S2666-5247(23)00406-8","article-title":"Pneumonia outbreaks due to re-emergence of Mycoplasma pneumoniae","volume":"5","author":"Meyer Sauteur","year":"2024","journal-title":"Lancet Microbe"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/S2666-5247(22)00190-2","article-title":"Mycoplasma pneumoniae beyond the COVID-19 pandemic: where is it","volume":"3","author":"Meyer Sauteur","year":"2022","journal-title":"Lancet Microbe"},{"key":"B20","doi-asserted-by":"publisher","first-page":"2300707","DOI":"10.2807\/1560-7917.ES.2024.29.2.2300707","article-title":"Mycoplasma pneumoniae epidemic in Denmark, October to December, 2023","volume":"29","author":"Nordholm","year":"2024","journal-title":"Euro Surveill."},{"key":"B21","doi-asserted-by":"publisher","first-page":"74","DOI":"10.7499\/j.issn.1008-8830.2009012","article-title":"Clinical features of children with Mycoplasma pneumoniae pneumonia and peripheral lymphocytopenia","volume":"23","author":"Peng","year":"2021","journal-title":"Zhongguo Dang Dai Er Ke Za Zhi."},{"key":"B22","doi-asserted-by":"publisher","first-page":"156","DOI":"10.23736\/S0026-4946.16.04866-0","article-title":"Diagnosis and treatment of Mycoplasma pneumoniae in children","volume":"69","author":"Rogozinski","year":"2017","journal-title":"Minerva Pediatr."},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.03009-23","article-title":"Exploring nasopharyngeal microbiota profile in children affected by SARS-CoV-2 infection","volume":"12","author":"Romani","year":"2024","journal-title":"Microbiol. Spectr."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1080\/22221751.2022.2078228","article-title":"Mycoplasma pneumoniae triggers pneumonia epidemic in autumn and winter in Beijing: a multicentre, population-based epidemiological study between 2015 and 2020","volume":"11","author":"Wang","year":"2022","journal-title":"Emerg. Microbes Infect."},{"key":"B25","doi-asserted-by":"publisher","first-page":"16926","DOI":"10.1038\/s41598-022-21430-x","article-title":"Lockdown measures during the COVID-19 pandemic strongly impacted the circulation of respiratory pathogens in Southern China","volume":"12","author":"Wang","year":"2022","journal-title":"Sci. Rep."},{"key":"B26","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/j.ccm.2018.07.003","article-title":"The lung microbiome and its role in pneumonia","volume":"39","author":"Wu","year":"2018","journal-title":"Clin. ChestMed."},{"key":"B27","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/j.jgg.2021.05.004","article-title":"Progressive deterioration of the upper respiratory tract and the gut microbiomes in children during the early infection stages of COVID-19","volume":"48","author":"Xu","year":"2021","journal-title":"J. Genet. Genomics"},{"key":"B28","doi-asserted-by":"publisher","first-page":"10872","DOI":"10.3390\/ijms221910872","article-title":"The lung microbiome during health and disease","volume":"22","author":"Yagi","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12519-023-00783-x","article-title":"Current status of Mycoplasma pneumoniae infection in China","volume":"20","author":"Yan","year":"2024","journal-title":"World J. Pediatr."},{"key":"B30","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.cytogfr.2004.01.001","article-title":"Cytokines in Mycoplasma pneumoniae infections","volume":"15","author":"Yang","year":"2004","journal-title":"Cytokine Growth Factor Rev."},{"key":"B31","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1007\/s12519-022-00592-8","article-title":"Pathogenic changes of community acquired pneumonia in a children\u2019s hospital in Beijing, China before and after COVID-19 onset: a retrospective study","volume":"18","author":"Zhang","year":"2022","journal-title":"World J. Pediatr."},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1088725","article-title":"Serum cytokine profiling reveals different immune response patterns during general and severe Mycoplasma pneumoniae pneumonia","volume":"13","author":"Zhang","year":"2022","journal-title":"Front. Immunol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1186\/s12879-023-08784-x","article-title":"Human microbiota dysbiosis after SARS-CoV-2 infection have the potential to predict disease prognosis","volume":"23","author":"Zhou","year":"2023","journal-title":"BMC Infect. Dis."},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1189647","article-title":"Immune response plays a role in Mycoplasma pneumoniae pneumonia","volume":"14","author":"Zhu","year":"2023","journal-title":"Front. Immunol."}],"container-title":["Frontiers in Cellular and Infection Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2024.1438777\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T09:02:11Z","timestamp":1737450131000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2024.1438777\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,21]]},"references-count":34,"alternative-id":["10.3389\/fcimb.2024.1438777"],"URL":"https:\/\/doi.org\/10.3389\/fcimb.2024.1438777","relation":{},"ISSN":["2235-2988"],"issn-type":[{"value":"2235-2988","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,21]]},"article-number":"1438777"}}